(Q34350145)

English

Adjunctive lisdexamfetamine dimesylate therapy in adult outpatients with predominant negative symptoms of schizophrenia: open-label and randomized-withdrawal phases

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

1 August 2017

Adjunctive lisdexamfetamine dimesylate therapy in adult outpatients with predominant negative symptoms of schizophrenia: open-label and randomized-withdrawal phases (English)

1 reference

Europe PubMed Central

1 August 2017

0 references

Henry Nasrallah

3

object named as

Henry Nasrallah

1 reference

Europe PubMed Central

1 August 2017

author name string

Robert A Lasser

1

1 reference

Europe PubMed Central

1 August 2017

Bryan Dirks

2

1 reference

Europe PubMed Central

1 August 2017

Courtney Kirsch

4

1 reference

Europe PubMed Central

1 August 2017

Joseph Gao

5

1 reference

Europe PubMed Central

1 August 2017

Michael L Pucci

6

1 reference

Europe PubMed Central

1 August 2017

Mary A Knesevich

7

1 reference

Europe PubMed Central

1 August 2017

Jean-Pierre Lindenmayer

8

1 reference

Europe PubMed Central

1 August 2017

language of work or name

0 references

publication date

8 May 2013

1 reference

Europe PubMed Central

1 August 2017

Neuropsychopharmacology

1 reference

Europe PubMed Central

1 August 2017

38

1 reference

Europe PubMed Central

1 August 2017

11

1 reference

Europe PubMed Central

1 August 2017

2140-2149

1 reference

Europe PubMed Central

1 August 2017

https://scigraph.springernature.com/pub.10.1038/npp.2013.111

0 references

Food and Drug Administration commentary on methodological issues in negative symptom trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3773663

6 July 2018

Negative symptoms in schizophrenia: avolition and Occam's razor

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3773663

6 July 2018

Dopamine hypothesis of schizophrenia: making sense of it all.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3773663

6 July 2018

Neurobiology of dopamine in schizophrenia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3773663

6 July 2018

Pharmacological treatment of negative symptoms of schizophrenia: therapeutic opportunity or cul-de-sac?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3773663

6 July 2018

Negative symptoms of schizophrenia: a problem that will not go away

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3773663

6 July 2018

The neurobiology of cognition in schizophrenia.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3773663

6 July 2018

The NIMH-MATRICS consensus statement on negative symptoms

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3773663

6 July 2018

Mechanism of action of antipsychotic drugs: from dopamine D(2) receptor antagonism to glutamate NMDA facilitation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3773663

6 July 2018

Stimulant psychosis: systematic review

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3773663

6 July 2018

Relapse prevention in schizophrenia with new-generation antipsychotics: a systematic review and exploratory meta-analysis of randomized, controlled trials.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3773663

6 July 2018

Increased dopamine transmission in schizophrenia: relationship to illness phases

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3773663

6 July 2018

The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3773663

6 July 2018

Partial improvement in negative schizophrenic symptoms after amphetamine

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3773663

6 July 2018

A rating scale for extrapyramidal side effects

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3773663

6 July 2018

The positive and negative syndrome scale (PANSS) for schizophrenia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3773663

6 July 2018

Provocative tests with psychostimulant drugs in schizophrenia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3773663

6 July 2018

The use of psychostimulants in general psychiatry. A reconsideration

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3773663

6 July 2018

Differential response to amphetamine in schizophrenia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3773663

6 July 2018

A rating scale for drug-induced akathisia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3773663

6 July 2018

Time course of transient behavioral depression and persistent behavioral sensitization in relation to regional brain monoamine concentrations during amphetamine withdrawal in rats

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3773663

6 July 2018

Treatment of negative schizophrenia with d-amphetamine.

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2013.111

21 January 2018

Lisdexamfetamine dimesylate: linear dose-proportionality, low intersubject and intrasubject variability, and safety in an open-label single-dose pharmacokinetic study in healthy adult volunteers

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2013.111

21 January 2018

Psychometric evaluation of the Amphetamine Cessation Symptom Assessment.

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2013.111

21 January 2018

Predictive values of neurocognition and negative symptoms on functional outcome in schizophrenia: a longitudinal first-episode study with 7-year follow-up.

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2013.111

21 January 2018

Ziprasidone and amisulpride effectively treat negative symptoms of schizophrenia: results of a 12-week, double-blind study.

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2013.111

21 January 2018

Amisulpride: Is There a Treatment for Negative Symptoms in Schizophrenia Patients?

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2013.111

21 January 2018

Double-blind, placebo-controlled study of the efficacy and safety of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3773663

27 October 2018

A depression rating scale for schizophrenics

1 reference

https://pubmed.ncbi.nlm.nih.gov/23756608

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1038/NPP.2013.111

1 reference

Europe PubMed Central

1 August 2017

Dimensions Publication ID

0 references

1 reference

Europe PubMed Central

1 August 2017

1 reference

Europe PubMed Central

1 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34350145&oldid=1955123698"